Labcorp Launches Plasma Complete for Personalized Cancer Care
Labcorp's New Offering Revolutionizes Cancer Treatment
Labcorp has recently announced the clinical availability of its cutting-edge service, Labcorp® Plasma Complete™. This advanced liquid biopsy test dramatically enhances how oncologists can guide treatment options for patients suffering from advanced solid tumors. With just a simple blood draw, this innovative solution allows for highly sensitive and specific genomic profiling.
Understanding the Benefits of Labcorp® Plasma Complete™
The Labcorp Plasma Complete test, which is based on circulating tumor DNA (ctDNA), empowers oncologists to perform comprehensive genomic profiling. This means more informed treatment decisions can be made with vital data gathered without needing a traditional tumor biopsy.
Expert Insights from Labcorp's Medical Leadership
Dr. Shakti Ramkissoon, who serves as the vice president and medical lead for oncology at Labcorp, highlighted the significance of this new offering by stating, "Labcorp Plasma Complete delivers powerful and comprehensive genomic insights and helps guide targeted treatment decisions even when tissue-based testing is not feasible." This service is a significant addition to Labcorp's extensive oncology portfolio, underscoring its commitment to personalized patient care.
Innovative Features of the Plasma Complete Test
The lab test can identify genomic alterations across 521 genes, covering both established and emerging biomarkers relevant to FDA-approved therapies and suitable clinical trials. This comprehensive approach not only aids in determining the most suitable treatments but also supports oncologists with crucial insights essential for delivering personalized care.
Streamlined Reporting for Oncologists
The flexibility provided by Labcorp Plasma Complete is further enhanced by its easily interpretable clinical reports powered by robust bioinformatics. This feature simplifies complex genomic data interpretation, saving oncologists precious time and resources in providing accurate patient care. Integrating this solution with Labcorp's extensive cancer diagnostic portfolio allows medical professionals to streamline decision-making across various stages of treatment.
Commitment to Research and Development
In addition to its application in patient care, Labcorp Plasma Complete will continue to be utilized in biopharmaceutical research. This dual application underscores the test's versatility and the company's dedication to advancing medical research. It has been validated within Labcorp's CAP-accredited and CLIA-certified laboratories, ensuring high-quality and reliable results.
Proven Accuracy and Reliability
Extensive validation studies published in reputable journals confirm the clinical accuracy and reliability of Labcorp Plasma Complete. The test demonstrates an exceptionally high specificity rate of over 99.99%, with the capability to detect tumor-specific biomarkers at variant allele frequencies as low as 0.1%. Such precision allows oncologists to identify actionable mutations, providing them with crucial information for effective treatment strategies.
Conclusion: A Breakthrough in Cancer Care
Labcorp is committed to advancing healthcare through its comprehensive laboratory services and innovations like Plasma Complete. By providing significant insights that lead to enhanced patient outcomes, Labcorp (NYSE: LH) stands at the forefront of reshaping cancer treatment protocols. Nearly 70,000 employees work tirelessly to support doctors, hospitals, and researchers, ultimately improving health and lives globally.
Frequently Asked Questions
What is Labcorp® Plasma Complete™?
Labcorp® Plasma Complete™ is a liquid biopsy test designed to provide comprehensive genomic profiling from a simple blood draw for patients with advanced solid tumors.
How does Labcorp Plasma Complete benefit oncologists?
The test offers sensitive and specific insights that help oncologists make informed treatment decisions without needing tissue biopsies.
How many genes does Labcorp Plasma Complete analyze?
The test can detect genomic alterations in 521 genes, encompassing both well-known and emerging biomarkers.
Is Labcorp Plasma Complete validated?
Yes, it has undergone rigorous validation in Labcorp's accredited laboratories to ensure its accuracy and reliability in clinical settings.
What is Labcorp's broader mission?
Labcorp focuses on improving health outcomes through innovative laboratory services and advanced diagnostics, serving a global client base.
About The Author
Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.